January 2025 clinical trial highlights
January 29, 2025
In the January 2025 clinical trial highlights, we'll showcase just a few of the many trials that are open for enrollment and seeking volunteers. To view more available trials for various forms of interstitial lung disease, please visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with progressive pulmonary fibrosis
MIST
- Study ID: NCT06329401
- Trial Phase: Phase 2
- Intervention: Inhaled drug
- Sponsor: Avalyn Pharma Inc.
- Study Contact: Craig S. Conoscenti, MD (206.707.0304, cconoscenti@avalynpharma.com); Daniele Tompkins (973.983.3700 ext. 205, dtompkins@devprobiopharma.com)
Seeking participants with idiopathic pulmonary fibrosis
ALOFT-IPF
- Study ID: NCT06003426
- Trial Phase: Phase 3
- Intervention: Oral drug
- Sponsor: Bristol-Myers Squibb
- Study Contact: Clinical.Trials@bms.com
Seeking participants with progressive pulmonary fibrosis
ALOFT-PPF
- Study ID: NCT06025578
- Trial Phase: Phase 3
- Intervention: Oral drug
- Sponsor: Bristol-Myers Squibb
- Study Contact: Clinical.Trials@bms.com
Seeking participants with idiopathic pulmonary fibrosis
TRANSFORM
- Study ID: NCT06317285
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: GlaxoSmithKline
- Study Contact: 877.379.3718, GSKClinicalSupportHD@gsk.com
Seeking participants with interstitial lung disease associated with connective tissue disease
BEconneCTD-ILD
- Study ID: NCT06572384
- Trial Phase: Phase 3
- Intervention: Subcutaneous injection
- Sponsor: GlaxoSmithKline
- Study Contact: 877.379.3718, GSKClinicalSupportHD@gsk.com
Research spotlight
To learn more about the five clinical trials featured in this newsletter, watch the Clinical Trial Innovation Series session hosted on Thursday, November 7, 2024, during the 2024 PFF Education Symposium. You will hear directly from the industry representatives running these research studies.
The purpose of the Clinical Trial Innovation Series is to provide up-to-date information about the development of innovative therapies and advancements in research to improve the lives of those living with pulmonary fibrosis (PF) and interstitial lung disease (ILD).